<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190693</url>
  </required_header>
  <id_info>
    <org_study_id>2018-003728-35</org_study_id>
    <nct_id>NCT04190693</nct_id>
  </id_info>
  <brief_title>IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo</brief_title>
  <acronym>IMCY-T1D-002</acronym>
  <official_title>IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imcyse SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imcyse SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the follow-up of study IMCY-T1D 001 (EudraCT: 2016-003514-27) in which patients
      with recent onset T1D have been treated with IMCY-0098 or placebo.

      At the end of the primary 6 month study, patients will be proposed to enter this follow-up
      study to evaluate up to 12 months (V3 - Week 48) the safety, the immune responses and the
      clinical parameters.

      The study involves a follow-up of 6 months after the end of the initial participation to the
      IMCY-T1D-001 study. Subjects will undergo visits at 24 weeks, 36 weeks and 48 weeks post
      first study product administration in study IMCY-T1D-001.

      For each patient, the study comprises a total of 3 visits occurring over a period of
      approximately 24 weeks (from study entry). The patients will undergo planned assessments and
      procedures as outlined in the table of study procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this LTFU study, the below objectives will be assessed 36 and 48 weeks after the first
      injection of IMCY-0098 in the study IMCY-T1D-001, in patients treated with IMCY-0098 at three
      doses or placebo:

      Primary Objective The primary objective of this study is to assess the long-term safety.
      Secondary Objective The secondary objective of this study is to evaluate the clinical
      response to IMCY-0098 by assessing disease activity.

      Exploratory Objectives

        -  To evaluate the proinsulin-specific cytolytic CD4+ T cells induced by IMCY-0098

        -  To evaluate the impact of IMCY-0098 on autoreactive T-cell responses specific for
           autoantigens expressed by islet β-cells (proinsulin, GAD65, IGRP) on the longer-term.

        -  To evaluate the impact of IMCY-0098 on autoantibodies against GAD65, IA 2, ZnT8 and
           insulin

        -  Transcriptomic analysis on mRNA extracted from samples collected for Immunogenicity
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Actual">November 18, 2019</completion_date>
  <primary_completion_date type="Actual">October 8, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Long-term follow-up, no study treatment administered.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Treatment or Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all adverse events reported for subjects</measure>
    <time_frame>Week 48</time_frame>
    <description>Occurrence, intensity and relationship of any systemic AEs throughout the study period in all treated groups versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of residual beta cell function</measure>
    <time_frame>Week 48</time_frame>
    <description>Measured by a change in stimulated C-peptide production from baseline and between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of daily insulin use</measure>
    <time_frame>Week 48</time_frame>
    <description>Measured by a change in the total daily use of all insulins (basal + short-acting) per kg of body weight from baseline and between groups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of T lymphocyte immune response to IMCY-0098</measure>
    <time_frame>Week 48</time_frame>
    <description>Comparison of changes in IMCY-0098 specific T lymphocyte responses longitudinally following peptide treatment and versus placebo.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Follow-up</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Investigational Medicinal Product will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMCY_0098</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No Investigational Medicinal Product will be administered during this LTFU study. Patients received treatment with IMCY-0098 in the primary study (IMCY-T1D-001).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMCY-0098 or placebo</intervention_name>
    <description>Long-term follow-up</description>
    <arm_group_label>Follow-up</arm_group_label>
    <arm_group_label>IMCY_0098</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who were treated with IMCY-0098 or placebo in the IMCY-T1D-001 clinical
             trial who are willing to participate to this long-term follow-up study.

        Exclusion criteria:

          -  Ongoing pregnancy or lactation

          -  History of or current malignancy (except excised basal cell skin cancer)

          -  Primary or secondary immune deficiency disorders

          -  Human Immunodeficiency virus (HIV) infection.

          -  Ongoing treatment with immunosuppressive agents with the exception of topical or intra
             nasal corticosteroids.

          -  Treatment with an investigational drug within the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Van Rampelbergh, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Imcyse SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg and Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GWT-TUD GmbH</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kauno klinikos</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital</name>
      <address>
        <city>Klaipėda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Center, CTC</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProbarE Stockholm</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Trust</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital (Barts Health NHS Trust)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle University</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Lithuania</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>to be disclosed later</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Q1-2020</ipd_time_frame>
    <ipd_access_criteria>to be disclosed later</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

